The prognostic relevance of p16 inactivation in head and neck cancer

被引:26
|
作者
Koscielny, Sven
Dahse, Regine
Ernst, Guenther
von Eggeling, Ferdinand
机构
[1] Univ Jena, ENT Dept, D-07740 Jena, Germany
[2] Univ Jena, Inst Human Genet & Anthropol, D-07740 Jena, Germany
[3] Helios Clin Erfurt GmbH, Inst Pathol, Erfurt, Germany
关键词
inactivation of p16; methylation of promoter region; loss of heterozygosity; head and neck cancer; tumor prognosis;
D O I
10.1159/000096714
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
The inactivation of the tumor suppressor gene p16 plays an important role in the development of malignant tumors. p16 loss can result from point mutations, loss of heterozygosity (LOH) or methylation of the promoter region. A total of 67 samples of tumor tissue from squamous cell carcinoma of the oral cavity, the pharynx and the larynx were analyzed for an inactivation of p16. The results of the molecular-biological investigations were correlated with the known clinical prognostic parameters after a follow-up period of approximately 3 years. Methylation of the promoter region and LOH were the main mechanisms of p16 inactivation. Point mutations presented as rare events. An inactivation of p16 did not have any statistical influence on tumor prognosis. Patients with a p16 gene inactivated by promoter methylation appeared to have a slightly lower tendency for local and regional recurrences. The inactivation of the tumor suppressor gene p16 plays a role in the carcinogenesis of head and neck cancer.
引用
收藏
页码:30 / 36
页数:7
相关论文
共 50 条
  • [31] High prevalence of p16 genetic alterations in head and neck tumours
    E C Miracca
    L P Kowalski
    M A Nagai
    British Journal of Cancer, 1999, 81 : 677 - 683
  • [32] High prevalence of p16 genetic alterations in head and neck tumours
    Miracca, EC
    Kowalski, LP
    Nagai, MA
    BRITISH JOURNAL OF CANCER, 1999, 81 (04) : 677 - 683
  • [33] P16 and HPV status in head and neck sarcomas and sarcomatoid carcinomas
    Shaker, Nuha
    Mansoori, Parisa
    Fattah, Yasmin H.
    Ellis, Monika
    Sexton, Tammy
    Neill, Stacey O. '
    Qasem, Shadi A.
    ANNALS OF DIAGNOSTIC PATHOLOGY, 2024, 71
  • [34] HPV and p16 in Mesenchymal Tumors and Sarcomatoid Carcinoma of the Head and Neck
    Mansoori, Parisa
    Frost, Ariel
    Zbieranski, Nora
    O'Neill, Stacey
    Qasem, Shadi
    AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2018, 149 : S96 - S97
  • [35] INACTIVATION OF P16 GENE IN LEUKEMIA
    陈文明
    朱嘉芷
    谭淑珍
    肖白
    刘敬忠
    Chinese Medical Sciences Journal, 1999, (04) : 15 - 19
  • [36] Inactivation of CdK-inhibitor P16 in non-small-cell lung cancer: Relevance of immunohistochemistry
    Brambilla, E
    Gazzeri, S
    Lantuejoul, S
    Gouyer, V
    Vour'ch, C
    Brambilla, C
    MODERN PATHOLOGY, 1998, 11 (01) : 171A - 171A
  • [37] Relationship between p16 and tumor-infiltrating lymphocytes in Peruvian patients with head and neck cancer
    Castaneda, C. A.
    Castillo Garcia, M.
    Bernabe, L. A.
    Sanchez, J.
    Tello, K.
    Alatrsita, R.
    Villa, L.
    Sichero, L.
    Enciso, J.
    Guerra, H.
    ANNALS OF ONCOLOGY, 2021, 32 : S802 - S802
  • [38] Estimating Impacts of p16 Status on Tumor Radiosensitivity in Head and Neck Cancer using Predictive Models
    Kaida, Atsushi
    Nojima, Hitomi
    Miura, Masahiko
    RADIATION RESEARCH, 2024, 202 (03) : 605 - 609
  • [39] The Prognostic Significance of p16 in Patients with Locoregionally Advanced Head and Neck Cancer Treated with Concurrent 5-Fluorouracil, Hydroxyurea, Cetuximab, and IMRT
    Lau, K.
    Tong, C. C. L.
    Rivera, M.
    Packer, S. H.
    Cannan, D.
    Teng, M. S.
    Sikora, A. G.
    Gupta, V.
    Genden, E. M.
    Kao, J.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 81 (02): : S485 - S486
  • [40] Frequent HPV-independent p16/INK4A overexpression in head and neck cancer
    Lechner, Matt
    Chakravarthy, Ankur R.
    Walter, Vonn
    Masterson, Liam
    Feber, Andrew
    Jay, Amrita
    Weinberger, Paul M.
    McIndoe, Richard A.
    Forde, Cillian T.
    Chester, Kerry
    Kalavrezos, Nicholas
    O'Flynn, Paul
    Forster, Martin
    Jones, Terry M.
    Vaz, Francis M.
    Hayes, D. Neil
    Fenton, Tim R.
    ORAL ONCOLOGY, 2018, 83 : 32 - 37